Crafting life changing therapies
Crafting life changing therapies
At Quell we see a future where serious immune-mediated and inflammatory disease can be durably controlled with a single dose of engineered Tregs.
Our Mission
Big challenges require dynamic, resilient teams.
Those who are both independent thinkers and passionate team players, those who are creative, resilient, and determined, and who have the courage to challenge the status quo.
Together, we will create the best therapeutics to harness the full potential of Tregs to treat serious immune and inflammatory diseases.
We are on a relentless pursuit to change and save lives.
Anchored by Values, Propelled by Purpose
People
A visionary team, passionately committed to delivering Quell's mission
Quell’s seasoned leadership team is dedicated to the delivery of transformative therapies to patients. Their extensive experience across all aspects of cell therapy development ensures continued leadership and innovation in the engineered Treg field.
Professor Sir Robert Lechler
Non-Executive Director
Alongside a distinguished career in academic medicine, Professor Sir Robert Lechler has embarked on a portfolio career, which includes acting as Non-Executive Director (NED) of NHS England, Co-Chairing the Board of SC1 London Life Sciences Innovation District, Chairing the Board of MiNA Therapeutics, and Chairing the Board of Directors of the London Mozart Players. He is also an Associate Director of the search firm, Alumni Global.
Previously, Sir Robert led the Life Sciences Faculties at King’s College London and founded and led King’s Health Partners Academic Health Science Centre for fifteen years. In 2015 he was elected as the President of the UK Academy of Medical Sciences, a post he held until 2020. In addition, he was a Founding Board Member of MedCity, was a Board Member of the Crick Institute, and a Trustee of the British Heart Foundation.
Sir Robert has made important scientific contributions to the field of transplantation and his leadership as a prominent clinical academic has had a major impact at local, national and international levels. Thus, in 2023, he was awarded the prestigious Thomas E. Starzl Prize in Surgery & Immunology. His contributions were recognised with a knighthood in 2012.
Our Partners
Partnering is in our DNA
We recognise that winning in a pioneering field means collaborating with the smartest people, to gain the best insights. At Quell, we look to partner with the leaders in their field, who share the common goal of accelerating life changing therapies to patients.
Biopharma
In the spirit of ‘partnering with the best’, Quell are always looking for world-leading pharma partners to collaborate with, sharing a clear goal of bringing together complimentary skill sets and knowledge bases, which together help us move the field forward, develop better therapeutics and change patients lives.
Quell’s recent collaboration with AstraZeneca is the perfect example of this - joining together on the journey to develop best-in-class therapies for type 1 diabetes and inflammatory bowel disease.
Academic
We understand that partnering with academia can help us unlock biologic insights, and optimise a highly translational product development cycle. If your lab is exploring the biology of Tregs which might unlock therapeutic approaches, we’d be keen to hear from you.
We collaborate with Kings College London, University College London, University Health Network, Hannover Medical School, University of Florida, University of Pittsburgh and many more.
Manufacturing
We can claim with real conviction that Quell understands Treg manufacturing better than any other organisation or institution on the planet. We got to this stage through collaboration with leading technology platforms, and academic / industrial partners. Together we are unlocking the platform for commercial scale Treg therapeutics.
Investors
Our Partners
At Quell we are passionate about our mission for bringing lifechanging immune-therapies of the future, into our world of today – We are pleased to be partnered with investors who collectively share our passion and our values.
